Loading provider…
Loading provider…
Hematology & Oncology Physician in Encino, CA
NPI: 1104183631Primary Employer
UCLA Medical Plaza
uclahealth.org
HQ Phone
Get M.D. John's Phone Numberphone_androidMobile
Get M.D. John's MobileLooking to connect with more Physicians?
Dmand AI gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Get Started for Freearrow_outwardCA State Medical License
2014 - 2025
CA State Medical License

American Board of Internal Medicine
Internal Medicine

American Board of Internal Medicine
Medical Oncology
Cedars-Sinai Medical Center
Residency • Internal Medicine
2012 - 2015
UCLA David Geffen School of Medicine/UCLA Medical Center
Fellowship • Hematology and Medical Oncology
Until 2018
UC Irvine School of Medicine
medschool.uci.edu
Medical School
Until 2012
Stanford University School Of Medicine
med.stanford.edu
Cancer Biology
—
| # | Procedure Code (CPT®/HCPCS II) | Procedure Patients | Procedure Volume |
|---|---|---|---|
| 1 | 99214Established patient office or other outpatient visit, 30-39 minutes | 239 | 539 |
| 2 | 99215Established patient office or other outpatient, visit typically 40 minutes | 193 | 458 |
| 3 | 85025Complete blood cell count (red cells, white blood cell, platelets), automated test | 136 | 279 |
| 4 | J9217Leuprolide acetate (for depot suspension), 7.5 mg | 92 | 760 |
| 5 | 80053Blood test, comprehensive group of blood chemicals | 87 | 157 |
Combinatorial CRISPR–Cas9 screens for de novo mapping of genetic interactions
Authors: John Paul Shen, Dongxin Zhao, Roman Sasik, Jens Luebeck, Amanda Birmingham, Ana Bojorquez-Gomez, Katherine Licon, Kristin Klepper, Daniel Pekin, Alex Beckett, Kyle S. Sanchez, Alex Thomas, Chih-Chung Kuo, Dan Du, Assen Roguev, Nathan E. Lewis, Aaron N. Chang, Jason F. Kreisberg, Nevan J. Krogan, Lei S. Qi, Trey Ideker, Prashant Mali
Publication Date: 2017-03
ERCC1 and TS Expression as Prognostic and Predictive Biomarkers in Metastatic Colon Cancer.
Lead Sponsor: MacroGenics
Intervention / Treatment: BIOLOGICAL: vobramitamab duocarmazine